Lung Cancer | Specialty

"Hitting the Target" Should Be Focus of Next-Generation Agents in Lung Cancer

July 26th 2019

The future generation of agents in lung cancer should be evaluated in improved predictive biomarker-driven trials to identify patients who are most likely to benefit or have detriment for both TKIs and checkpoint inhibitors.

Dr. Reckamp on Pivotal Data in METex14-Altered NSCLC

July 26th 2019

Karen L. Reckamp, MD, MS, discusses pivotal findings with the highly selective MET inhibitors, tepotinib and capmatinib in patients with MET exon 14-altered advanced non–small cell lung cancer.

Future Lung Cancer Research Requires Precision Medicine Ecosystem

July 26th 2019

There is a growing need to share information across research settings and the community, with the rapid introduction of new biomarkers, cancer detection strategies, immunotherapies, and targeted therapies. This synchronization of system biology tool datasets could help create a new digital ecosystem focused on precision medicine.

Novel Research Methods Could Expedite New Drug Development

July 26th 2019

Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic.

Multidisciplinary Effort Key to Successful Lung Cancer Screening Programs

July 24th 2019

Mollie Meek, MD, highlights key lung cancer screening trials, offered insight into how to successfully implement an effective program, and stressed that collaboration is critical in order to provide the best patient care.

New Agents Emerge for Elusive NSCLC Targets

July 22nd 2019

Although immunotherapy has become an important modality for treating non–small cell lung cancer, the development of new strategies for targeting oncogenic drivers of disease in subgroups of patients is moving forward at a brisk pace.

Treatment of NSCLC With RET Fusions

July 19th 2019

The NTRK Family of Fusions in NSCLC

July 19th 2019

Treatment of NSCLC Rare Genotypes

July 19th 2019

ROS1-Rearranged NSCLC

July 19th 2019

Managing CNS Disease in ALK-Rearranged NSCLC

July 19th 2019

ALK-Rearranged Lung Cancer

July 19th 2019

Novel EGFR Exon 20 Directed Therapies for NSCLC

July 19th 2019

RELAY: Erlotinib with Ramucirumab for EGFR+ NSCLC

July 19th 2019

Novel EGFR Inhibitor Combinations for NSCLC

July 19th 2019

Treating EGFR+ NSCLC Brain Metastases

July 19th 2019

EGFR-Mutated NSCLC; Where We Are Now?

July 19th 2019

How Are We Using Liquid Biopsy in NSCLC?

July 19th 2019

Molecular Testing for Patients With Symptomatic NSCLC

July 19th 2019

Acting on Molecular Testing Results in NSCLC

July 19th 2019